Navigation Links
Sangart Announces Closing of $50 Million Series G Financing
Date:4/19/2011

SAN DIEGO, April 19, 2011 /PRNewswire/ -- Sangart, Inc., today announced that it recently received more than $50 million in new equity funding from existing investors, led by Leucadia National Corporation. The most recent investment brings the total funding raised by the company since its inception in 1998 to more than $230 million. This financing round also included warrants which, if exercised, could provide up to an additional $50 million in future funding.

Funds raised in this Series G round will be used to advance the development of the MP4OX product in severe traumatic hemorrhage and the MP4CO product in sickle cell disease. MP4OX is an investigational biopharmaceutical designed to enhance the perfusion of oxygen-deprived (ischemic) tissues and provide targeted oxygen delivery in the capillaries. MP4CO is an investigational biopharmaceutical designed to deliver therapeutic levels of carbon monoxide (CO) to patients suffering from a sickle cell crisis.

"We are encouraged by this level of support from our existing investors, who recognize the clinical potential of our products," said Brian O'Callaghan, President and CEO of Sangart. "This funding will allow us to continue advancing the development of our medicines and get them as quickly as possible to patients in need. We continue to see promise in our MP4-based medicines in the treatment of patients who experience an acute traumatic injury and in patients with sickle cell disease suffering from a vaso-occlusive crisis."

About MP4Sangart's product platform is based on the MP4 molecule, an investigational biopharmaceutical product designed to enhance the perfusion of oxygen-deprived (ischemic) tissues and provide targeted oxygen delivery in the capillaries. Using a novel pegylation approach, Sangart produces the MP4 molecule designed at the optimal oxygen affinity, diffusion potential and molecular size to perfuse capillaries and target oxygen delivery to tissues specifically at risk of ischemia. MP4 can also deliver precise amounts of carbon monoxide to the red blood cells of patients with sickle cell disease, stabilizing their hemoglobin. Carbon monoxide can also act as a gasotransmitter with anti-inflammatory properties. Once the carbon monoxide is delivered, the MP4 is oxygenated in the lungs and can then carry oxygen for targeted delivery to ischemic tissues.

About SangartSangart is a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen delivery. Based on more than a decade of research, Sangart has refined the pegylation of human hemoglobin to create a molecule, MP4, with the ability to carry oxygen or carbon monoxide through the circulatory system to prevent and treat ischemia and to stabilize the hemoglobin of sickle cell disease patients.

To learn more about Sangart, please visit the company's website at www.sangart.com.Media Contact:Marites Cristobal CoulterEdelman Public Relations

Office: 323-202-1424Marites.Cristobal@edelman.com

Cell: 415-819-2214
'/>"/>

SOURCE Sangart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangart, Inc. Receives U.S. Orphan Drug Designation for use of MP4CO in Patients with Sickle Cell Disease
2. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
3. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
4. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
5. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
6. MiMedx Group, Inc. Announces Release Date for First Quarter Results
7. Awarepoint Corporation Announces Acquisition of PCTS
8. Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences
9. Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection
10. CryoLife Announces Release Date and Teleconference Call Details for 2011 First Quarter Financial Results
11. Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016 , Net Sales of $1.90 billion ... the prior year period, and an increase of 1.2% on ... EPS for the first quarter were $0.52 reported, a decrease ... an increase of 29.9% over the prior year period ... guidance for 2016 Zimmer Biomet Holdings, Inc. (NYSE ...
(Date:4/28/2016)... , April 28, 2016 TapImmune,Inc. ... of innovative peptide and gene-based immunotherapeutics and vaccines for the ... be presenting at the 3rd Annual Growth Capital Expo ... th , 2016 at Caesars Palace in Las Vegas, Nevada.  ... on Wednesday, May 4 th by Dr. John ...
(Date:4/27/2016)... --   , Total Sales ... Sales  Clinical sales grow 16% year-over-year  , ... OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser ... quarter ended March 31, 2016 and provided an update ... strategy. First Quarter 2016 Revenue Results by ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... Trinity ... Tobacco-Free Kids, a leading force in the fight to reduce tobacco use and ... policies that can help reduce tobacco use. The initiative brings together two organizations ...
(Date:4/28/2016)... Illinois (PRWEB) , ... April ... ... the leading provider of enterprise Data Center Infrastructure Management solutions, announces today ... focuses on feature enhancements in the area of capacity management and optimization, ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Aesthetic Surgery Education and Anzu®, developers of the AnzuMedical™ Knowledge Sharing and ... Surgery Collaborative Residency Network. The platform is scheduled to launch in July 2016 ...
(Date:4/28/2016)... ... April 28, 2016 , ... Accreditation Commission ... Oncology Pharmacy Association (COPA) to develop a comprehensive Specialty Pharmacy Accreditation with Distinction ... an accreditation distinction. ACHC provides a wide range of pharmacy accreditation services that ...
(Date:4/28/2016)... D.C. (PRWEB) , ... April 28, 2016 , ... The ... and Prevention (CDC) has established an ICD-10-CM code for sarcopenia, giving it recognition for ... the medical community effective October 1, 2016. , Sarcopenia is defined as a combination ...
Breaking Medicine News(10 mins):